SYNLAB offers a full range of medical laboratory services for practising doctors, clinics and the pharmaceutical industry. Formed through a combination of Labco and synlab, the new SYNLAB Group is the uncontested leader on the European market for human medicine laboratory services. SYNLAB particularly focuses on the implementation of innovative laboratory medicine methods and on networking specialist diagnostic competences (SYNLAB Centres of Excellence). SYNLAB maintains additional laboratories (strategic business units) in individual countries for veterinary medicine and environmental analysis. This services portfolio is rounded off by expert medical imaging centres in certain countries. The group works closely with research institutions and universities and also maintains an educational institution of its own, the SYNLAB Academy.
SYNLAB has eight Anatomic Pathology laboratories in Spain and Portugal, added to the over 550 laboratories distributed along 30 countries. Thus, SYNLAB stands out as one of the organizations with the highest number of specialists in Europe (more than 120). Considered alone, 52 expert pathologists of national and international renowned prestige are part of the Iberian SYNLAB network.
Thanks to medical experts team, the different areas of Anatomical Pathology and Molecular Pathology knowledge are covered, allowing a specialization level not comparable to any other laboratory network.
In this innovation environment, in addition to the usual range of services, SYNLAB offers the following advantages:
SYNLAB's Cancer Molecular Pathology laboratory is integrated in the Anatomical Pathology área, to provide a complete diagnosis oriented towards Personalized and Precision Medicine. The laboratory portfolio covers over 150 different molecular analyses, intended to define the diagnosis, establish disease prognosis and monitor the patient’s response to targeted therapies.
According to the analyses performed, the physician will obtain information regarding:
Another advantage of SYNLAB's service is the possibility to work with any type of sample: paraffin-embedded tissues, frozen tissues, cytological samples, serum and/or plasma, platelets and cerebrospinal fluid, among others.
The portfolio includes more than 110 individual gene analyses (both by FISH and PCR) as well as several panels (the analyses of a group of genes). The panels can be either pancancer or tissue related.
Some of the analysis included in the portfolio are: the Prosigna test, an accionable panel, a tumour mutation profile,, a lung fusion panel, a somatic breast panel, a somatic colon (basic, complete or extended) panel, a somatic melanoma (basic or extended) panel, a somativ glioma panel, a somatic lung (small cell, no tobacco or complete) panel, a somatic GIST panel and a somatic ovarian panel.
The Prosigna test is a breast cancer prognostic gene signature assay based on PAM50. The molecular assay measures the gene expression of 50 genes and allows tumour classification into one of 4 intrinsc subtypes ((Luminal A, Luminal B, Her2-enriched or Basal-like). The intrinsic subtype is directly related to prognosis and is key to determine the type of treatment. The test also provides information about the Risk of Recurrence (ROR) and the 10-years probability of distant recurrence. Therefore, the test gives the oncologist key information to determine the best treatment for the patient.
The Accionable Panel allows the detection of 773 variants (either SNVs or small (<200bp) insertions and deletions) in 12 genes, and it can be performed in all solid tumor types. The information obtained helps the oncologist to determine the patient's most appropiate therapy.
The Tumor Mutation Profile allows the detection of 223 mutations in 63 oncogenes and tumor supresor genes, and it can be performed in all solid tumor types. Thus, the analysis detects both known mutations and mutations related to novel targeted therapies in the pipeline. Also, the information obtained helps the oncologist to determine the patient's most appropiate treatment.
The SYNLAB Liquid Biopsy Service is a comprehensive option available for solid tumours, the objective of which is to provide a diagnostic solution with high added value. From a single blood draw, the oncologist will learn accurate and actionable information regarding the mutations present in the tumour, during the different periods of tumour evolution: at diagnosis, during follow-up and at progression.
A tumour tissue sample (biopsy) is normally used at the time of diagnosis to study the mutational state of the tumour. But this strategy has several problems: in some cases it is not possible to perform a tumour biopsy, and not enough material is obtained in all biopsies to carry out the different analyses.
To address these inconveniences, the SYNLAB Liquid Biopsy Service offers a comprehensive NGS panel, which includes all NCCN mutations recommended for solid tumours and detects all 4 major types of somatic mutations: SNVs (Single Nucleotide Variants), CNV (Copy Number Variations), insertions and deletions (indels), and fusions. The test provides useful information on activating alterations, alterations related to mechanisms of therapy resistance, and alterations that can make the patient a suitable candidate for a clinical trial.
For the monitoring process, SYNLAB offers a targeted and personalized study, also based on free tumoral DNA in blood. This analysis evaluates only those mutations detected at the time of diagnosis. This approach implies a clear benefit to the patient, since it requires less blood volumen, less need for image tests, and a considerable cost reduction. But it is also posible to include in this analysis the study of certain alterations related to treatment resistance, since resistance changes can be detected before clinical progression and thus predict disease progression. Therefore, this option allows a complementary analysis during treatment and gives the oncologist an early opportunity to modify treatment. This fact, coupled with the ability of the techniques to quantify the patient’s tumour burden, may allow a very early approach to possible relapses.
The importance of knowing the molecular mechanisms involved in disease progression is now being confirmed. Studying the molecular changes that the tumour undergoes, allows to learn the alterations involved in invasion, metastasis and relapse, and provides information on how to interfere in these processes. On the other hand, tumour heterogeneity is not usually considered at the time of diagnosis, although there is evidence of the existence of multiple tumour subclones, especially in the advanced stages of the disease. Hence, many patients develop partial responses to treatments.
Therefore, the SYNLAB Liquid Biopsy Service can be used to perform a second screening with NGS at the time of treatment progression, to determine actionable mutations and resistance mechanisms. This will allow the study of the tumour molecular evolution, as well as the identification of new mutations or mechanisms of treatment resistance.
BRCA + 16 genes, COLON + and NGS Hereditary cáncer panel
SYNLAB DIAGNOSTICOS GLOBALES has not received any reviews.
SYNLAB DIAGNOSTICOS GLOBALES has not received any endorsements.